Pamela Kunz

Pamela Kunz leads the Yale Cancer Center's NET program and has contributed extensively to the clinical management of carcinoid syndrome and its cardiac complications. She has led studies of somatostatin analog dose optimization, telotristat ethyl for carcinoid syndrome, and novel combination approaches. Her research also encompasses patient-reported outcomes and quality of life in NET patients managing chronic symptoms. She is a member of multiple national and international NET guideline groups.